- Home
- Publications
- Publication Search
- Publication Details
Title
The mTOR Signalling Pathway in Human Cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 13, Issue 2, Pages 1886-1918
Publisher
MDPI AG
Online
2012-02-11
DOI
10.3390/ijms13021886
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Differential Involvement of I B Kinases and in Cytokine- and Insulin-Induced Mammalian Target of Rapamycin Activation Determined by Akt
- (2014) H. C. Dan et al. JOURNAL OF IMMUNOLOGY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer
- (2011) Jae Hong No et al. GYNECOLOGIC ONCOLOGY
- Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group
- (2011) Amit M. Oza et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy
- (2011) Phuong K. Morrow et al. JOURNAL OF CLINICAL ONCOLOGY
- PKI-179: An orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor
- (2010) Aranapakam M. Venkatesan et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Mammalian Target of Rapamycin Activator RHEB Is Frequently Overexpressed in Human Carcinomas and Is Critical and Sufficient for Skin Epithelial Carcinogenesis
- (2010) Z. H. Lu et al. CANCER RESEARCH
- New Strategies in Estrogen Receptor-Positive Breast Cancer
- (2010) S. R. D. Johnston CLINICAL CANCER RESEARCH
- The Complexes of Mammalian Target of Rapamycin
- (2010) Hongyu Zhou et al. CURRENT PROTEIN & PEPTIDE SCIENCE
- Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound26(PKI-587), a Highly Efficacious Dual Inhibitor
- (2010) Aranapakam M. Venkatesan et al. JOURNAL OF MEDICINAL CHEMISTRY
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
- (2010) T E Witzig et al. LEUKEMIA
- Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations
- (2010) Miyako Hiramatsu et al. LUNG CANCER
- Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma
- (2010) Helena Pópulo et al. MELANOMA RESEARCH
- Termination of autophagy and reformation of lysosomes regulated by mTOR
- (2010) Li Yu et al. NATURE
- Alterations in VHL as potential biomarkers in renal-cell carcinoma
- (2010) Lucy Gossage et al. Nature Reviews Clinical Oncology
- Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer
- (2010) T Sato et al. ONCOGENE
- mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics
- (2010) H. Pópulo et al. Pigment Cell & Melanoma Research
- Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
- (2009) Juan M. García-Martínez et al. BIOCHEMICAL JOURNAL
- Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity
- (2009) L J Coleman et al. BRITISH JOURNAL OF CANCER
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin
- (2009) K. Yu et al. CANCER RESEARCH
- DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival
- (2009) Timothy R. Peterson et al. CELL
- Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma
- (2009) Premal H. Patel et al. Clinical Genitourinary Cancer
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
- (2009) Carson C. Thoreen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
- (2009) Susan L. Ellard et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
- (2009) David A. Reardon et al. JOURNAL OF NEURO-ONCOLOGY
- The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma
- (2009) Ledu Zhou et al. MEDICAL ONCOLOGY
- NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
- (2009) T.-J. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
- (2009) David E. Harrison et al. NATURE
- The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma
- (2009) SubbaRao V. Madhunapantula et al. Pigment Cell & Melanoma Research
- Caloric Restriction Delays Disease Onset and Mortality in Rhesus Monkeys
- (2009) R. J. Colman et al. SCIENCE
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- Hsp70 associates with Rictor and is required for mTORC2 formation and activity
- (2008) Jheralyn Martin et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- A novel AKT3 mutation in melanoma tumours and cell lines
- (2008) M A Davies et al. BRITISH JOURNAL OF CANCER
- Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002
- (2008) J. Werzowa et al. BRITISH JOURNAL OF DERMATOLOGY
- S6K1 Plays a Key Role in Glial Transformation
- (2008) J. L. Nakamura et al. CANCER RESEARCH
- Akt3 and Mutant V600EB-Raf Cooperate to Promote Early Melanoma Development
- (2008) M. Cheung et al. CANCER RESEARCH
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
- (2008) K. Stemke-Hale et al. CANCER RESEARCH
- Autophagy in the Pathogenesis of Disease
- (2008) Beth Levine et al. CELL
- The IκB kinase – a bridge between inflammation and cancer
- (2008) Michael Karin CELL RESEARCH
- A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies
- (2008) D. A. Rizzieri et al. CLINICAL CANCER RESEARCH
- Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin
- (2008) B. I. Rini CLINICAL CANCER RESEARCH
- Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
- (2008) Timothy A Yap et al. CURRENT OPINION IN PHARMACOLOGY
- The RSK factors of activating the Ras/MAPK signaling cascade
- (2008) Audrey Carriere Frontiers in Bioscience-Landmark
- Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
- (2008) Brian M. Wolpin et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
- (2008) Andrea Molckovsky et al. Journal of Hematology & Oncology
- Combined Inhibition of MAPK and mTOR Signaling Inhibits Growth, Induces Cell Death, and Abrogates Invasive Growth of Melanoma Cells
- (2008) Konstantinos G. Lasithiotakis et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)
- (2008) Teri N. Kreisl et al. JOURNAL OF NEURO-ONCOLOGY
- The TSC1-TSC2 Complex Is Required for Proper Activation of mTOR Complex 2
- (2008) J. Huang et al. MOLECULAR AND CELLULAR BIOLOGY
- AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
- (2008) Dana M. Gwinn et al. MOLECULAR CELL
- Autophagy fights disease through cellular self-digestion
- (2008) Noboru Mizushima et al. NATURE
- Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors
- (2008) L S Steelman et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now